In the early days of the second Trump administration, what will happen to various government science agencies is not yet clear. Given the communications blackout imposed on agencies including the NIH and the CDC, most of what is known comes from anonymous sources and secondhand reports. Executive orders affecting the agencies are also still in the process of being interpreted, as well as subject to multiple legal challenges.
Researchers at the University of California at San Francisco have identified an RNA-binding protein that increased the translation of Myc mRNA. The authors wrote that their work, which was published online in Nature Cell Biology on Feb. 4, 2025, “transforms the understanding of the translational code in cancer and illuminates therapeutic openings to target the expression of oncogenes.”
Researchers at the University of California at San Francisco have identified an RNA-binding protein that increased the translation of Myc mRNA. The authors wrote that their work, which was published online in Nature Cell Biology on Feb. 4, 2025, “transforms the understanding of the translational code in cancer and illuminates therapeutic openings to target the expression of oncogenes.” Myc is a transcription factor that regulates multiple cellular growth factors. Its overexpression is a driver event in many solid tumors, including pancreatic cancer. Drugging Myc, though, has so far proved challenging.
Implanted patches of iPS cell-derived heart muscle integrated with heart tissue in a primate model of heart failure, and in patients being treated in a clinical trial, marks progress toward a potential option for patients with advanced heart failure.
Implanted patches of iPS cell-derived heart muscle integrated with heart tissue in a primate model of heart failure, and in patients being treated in a clinical trial, marks progress toward a potential option for patients with advanced heart failure.
Implanted patches of iPS-derived heart muscle integrated with heart tissue in a primate model of heart failure, and in patients being treated in a clinical trial, marks progress toward a potential option for patients with advanced heart failure.
At his confirmation hearing, Robert F. Kennedy Jr., the nominee for secretary of the U.S. Department of Health and Human Services, claimed that he is not anti-vaccine. But his record does not bear that out. Kennedy is a longstanding vaccine denier, and in 2021 was identified as one of the “Disinformation Dozen” – the 12 accounts responsible for the majority of disinformation about COVID-19 vaccines on social media platforms – by the British-American nonprofit Center for Countering Digital Hate.
A global commission has proposed a fundamental change to the way obesity is defined and diagnosed. If the change is implemented, obesity would be considered a health risk in some contexts, and a disease in others. “The commission is reframing obesity... in a way that allows for the nuanced reality of obesity,” Robert Eckel told reporters at a press briefing announcing the proposal, which was published online in The Lancet Diabetes & Endocrinology on Jan. 14, 2025.
The largest analysis to date of patients taking GLP-1 receptor agonists (GLP-1RAs) has investigated their effects on nearly 175 diseases, and found that compared to three other classes of diabetes medications, individuals with a prescription for GLP-1RAs had a reduced risk of 42 diseases, and an increased risk of 19.
The largest analysis to date of patients taking GLP-1 receptor agonists (GLP-1RAs) has investigated their effects on nearly 175 diseases, and found that compared to three other classes of diabetes medications, individuals with a prescription for GLP-1RAs had a reduced risk of 42 diseases, and an increased risk of 19. The findings, which were published Jan. 20, 2025, in Nature Medicine, provide a comprehensive overview of GLP-1RAs’ effects.